^
Association details:
| Biomarker: | PGBD5 underexpression |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | ceralasertib (AZD6738) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors
Excerpt:
Consistent with the relatively low expression of PGBD5 in PDX1 neuroblastoma tumor (Fig. 7B), we found that single-agent treatment with AZD6738 or cisplatin had no effect, whereas combination of AZD6738 with cisplatin exhibited significant reduction in tumor growth, as compared to single-agent or vehicle control treatments (P = 1.9 × 10−3; Fig. 7C).
Secondary therapy:
cisplatin
DOI:
10.1126/scitranslmed.aam9078
